Abstract
Introduction

Breast cancer is a genetic disease caused by the accumulation of mutations in neoplastic cells
. Genetic analyses have for long been performed in breast cancer research in order to unravel the molecular aberrations leading to tumour initiation and progression [1, 3, 4] . In the last few years, increasingly more coherent information about genetic aberrations in breast cancer has been generated and molecular techniques are slowly becoming part of the diagnostic and prognostic armamentarium available for pathologists and oncologists to tailor the therapy for breast cancer patients.
Despite the advancements, it should be noted that breast cancer management still relies on clinico-pathological features (i.e. tumour size, histological grade and presence of axillary lymph node metastasis) and three immunohistochemical markers (oestrogen receptor [ER], progesterone receptor [PR] and HER2)
for treatment decision-making) [5, 6] . However, it has become clear in the last years that these parameters are not sufficient to tailor therapy for individual patients and a more predictive model is needed.
Since the development of approaches for high-throughput molecular analysis in the 90s, studying the whole genome and transcriptomic of cancers in a single experiment has become a reality [5, 6] [7] [8] [9] [10] . [19] .
. This technological advancement has led to a paradigm shift in cancer research: from a reductionist approach where single genes/ proteins could explain complex phenotypes, to a model where phenotypic characteristics are explained by the interaction of multiple genetic, epigenetic and transcriptomic aberrations. Furthermore, these methods have provided a unique opportunity to unravel the molecular underpinning of the histological characteristics of cancers and their clinical behaviour. In fact, seminal high-throughput genetics and transcriptomic studies have brought to the forefront of breast cancer research the concept that breast cancer is a heterogeneous disease and provided some tantalizing evidence to suggest that there is a high degree of phenotypic-genotypic correlations in breast cancer
Several reviews have addressed the contribution of highthroughput expression profiling to our understanding of breast genes appears to be the major difference between each subgroup (low in luminal A and high in luminal B). Although the separation of luminal tumours in two subgroups of prognostic significance is appealing, a recent large meta-analysis of published available expression data suggested that luminal tumours form a continuum and that the separation of these tumours into two subgroups based on proliferation is arbitrary
The ER-negative cluster appears to be substantially more heterogeneous. In the studies carried out by the Stanford group, three different subtypes were identified: normal breast-like cancers, HER2 and basal-like. Normal breast-like cancers are rather poorly characterized and their clinical significance is yet to be determined [12, 13, [16] [17] [18] . Some have suggested that this subgroup may be a mere artefact of expression profiling (i.e. a disproportionally high content of stromal cells) [20] , given that identification of this group of tumours by microarrays is less stable when fine needle aspiration biopsies are used [21] [13, 21] , not all tumours that are HER2-amplified fall into the HER2 cluster by expression arrays analysis. There is also evidence to suggest that some HER2-amplified, ER-positive cancers fall within the luminal B subtype rather than the HER2-microarray subtype [20, 21] . Basallike subtype is the third group in the ER-negative cluster and is so named because the neoplastic cells of this tumour type consistently express genes usually found in normal basal/ myoepithelial cells of the breast, including high molecular weight cytokeratins (5/6 and 17) , P-cadherin, caveolins 1 and 2 [22] [23] [24] [25] [26] [27] [28] [29] , nestin [30] and epidermal growth factor receptor (EGFR) [24] and, in a minority of cases, harbour EGFR gene amplification [12] or aneusomy [31] . These [12, 13, [16] [17] [18] [50] [51] [52] [53] [54] [20, 24, 43, 49, 55, 56] [6, 11] [19, [75] [76] [77] [78] [79] . Wirapati et al. [19] have not only confirmed that different prognostic signatures identify similar groups of breast cancer patients, but also that the assignment of patients into good or poor prognosis is largely dependent on the expression levels of genes pertaining to the 'proliferation cluster'. Some signatures performed even better when only the proliferation-related genes were used to predict prognosis [19] . Another conclusion drawn from these analyses is that the prognostic power of most classifiers is limited to the subgroup of ER-positive/ HER2-negative subgroup [19, 76] , providing another line of evidence that proliferation is the major determinant of prognosis in this subgroup of patients. [1, 80] 
or when microdissected samples are subjected to expression array analysis (JS Reis-Filho and R Natrajan, unpublished observations). The HER2 and basal-like subtypes have in common an aggressive clinical behaviour. HER2 tumours are characterized by overexpression of HER2 and genes associated with HER2 pathway and/or HER2 amplicon on 17q12. Although the vast majority (Ͼ80%) of HER2 cancers as defined by microarrays harbour HER2 gene amplification or HER2 3ϩ immunohistochemical expression
High-throughput genetic analysis
The concept that breast cancer encompasses a plethora of entities with distinctive biological characteristics and clinical behaviour is also underpinned at the molecular genetic level by a complex array of genetic alterations that affect the function and control of individual genes and cellular processes
Phenotypic-genotypic correlations
The study of the molecular genetics and the phenotypic diversity of breast cancers has revealed interesting genotypic-phenotypic correlations [10, 96- [17, 108, 109] . In addition, tumours from BRCA1 mutation carriers cluster predominantly in the basallike group by gene expression profiling [18, 110] . Taken together, there is evidence to suggest a strong genotypic-phenotypic correlation between BRCA1 and the basal-like phenotype [28, 41, 98, [111] [112] [113] . This genotypic-phenotypic correlation has been further confirmed by the development of two conditional mouse models, where Brca1 and Trp53 were inactivated either in the basal or luminal cells of the mouse mammary gland [8, 9] . These transgenic animals [8, 9] developed tumours whose histopathological, immunohistochemical and transcriptomic characteristics recapitulated the cardinal features of human basal-like breast cancers (Fig. 2) . The analysis of lobular neoplasia and invasive lobular cancers has also revealed an important genotypic-phenotypic association in breast cancer [114, 115] [7] . Pure micropapillary carcinoma is another rare special type of breast cancer, which constitutes a distinct entity at the morphological, transcriptomic [124] [134] [135] [136] [137] [138] [139] [140] and its amplification seems to be limited to HER2-amplified tumours [93, 135, 136, 139, 140] . HER2 status has been reported to predict response to anthracycline-based chemotherapy [141] [142] [143] [144] 137, 139, 145] . However, data are still contradictory and TOP2A deletions have also been shown to be associated with 13-43% of HER2-amplified tumours [134] [135] [136] [137] [138] and potentially to mediate sensitivity to anthracyclines [137] . Recent studies have been published with discordant results. O'Malley et al. [138] [146] . PPM1D activation results in a negative regulation of p53 function and other tumour suppressor pathways, by selective inactivation of p38 kinase [147, 148] . Furthermore, additional functions of PPM1D contributing to its oncogenic effect include regulation of the base excision pathway of DNA repair [149] , progesterone receptor function [150] and the regulation of the cell cycle and DNA repair-associated CHK1, CHK2 and ATM kinases [149, [151] [152] [153] . PPM1D has also been linked with regulation of NFB signalling [154] and loss of PPM1D function has been shown to sensitize cells to stress-and DNA damageinduced apoptosis [155] . Recently 
and genetic levels [100], indicating genotypic-phenotypic correlation. Morphologically, micropapillary carcinomas display a characteristic growth pattern of cell clusters with inverted polarity and are associated with a higher prevalence of lympho-vascular invasion and lymph node metastatic deposits. Unsupervised hierarchical clustering of gene expression profiles of distinct special types of breast cancer revealed that micropapillary carcinomas formed a separate cluster [124]. In addition, immunohistochemical and aCGH analyses [100] revealed that these cancers display a luminal B phenotype and have a distinct pattern of genetic aberrations when compared to that of ERand grade-matched invasive ductal carcinomas, providing strong circumstantial evidence that micropapillary morphology is not a mere histological pattern but actually identifies a discrete molecular entity [100, 101]. Interestingly, the analysis of mixed tumours with areas of micropapillary differentiation admixed with other growth patterns revealed remarkably similar patterns of genetic aberrations and immunohistochemical profiles between the papillary and non-papillary components of each tumour [101]. This is in agreement with previous studies suggesting that the presence of a micropapillary component, even in the form of a small focus in an invasive ductal carcinoma, is associated with a pattern of metastases and clinical behaviour similar to those of pure micropapillary carcinomas [101].
Biomarkers and therapeutic targets
Molecular studies have confirmed the importance of these three biomarkers and there are several lines of evidence to suggest that breast cancer comprises at least two distinct diseases (ER-positive and ER-negative). Studies aiming to identify new biomarkers and therapeutic targets, and/or evaluate response to therapy should take into account the distinctive molecular features of the different subtypes, otherwise they risk under-or overestimating their performance [94, 126, 127]. Specific molecular pathways and networks may be important in one particular molecular subtype, such as proliferation-related genes in ER-positive cancer, but not in others (e.g. proliferation-related genes in ER-negative cancers) [76]. Following the multitude of profiling studies on breast cancer, several new biomarkers and potential therapeutic targets have been identified. It is likely that in the future
8p11-p12 amplicon
The 8p11-p12 region is reported to be amplified in 10-15% of breast cancers and is correlated with histological grade, proliferation rates and poor prognosis [156] [157] [158] [159] . The expression and signalling of at least two genes in this amplicon have been shown to be required for the survival of cancer cells harbouring 8p11.2-p12 amplification: FGFR1, a tyrosine kinase receptor [120] , and PPA-PDC1B, a transmembrane phosphatase [160] . Although these genes constitute promising therapeutic targets, further clinical validation is required to establish whether inhibition of these genes in 8p11.2-p12-amplified cancers is a suitable therapeutic strategy for a subgroup of breast cancer patients.
BRCA1, basal-like tumours and PARP inhibitors
BRCA1 and BRCA2 function is required for competent DNA double-strand breaks repair by homologous recombination, which is an accurate mechanism of DNA repair [112, 161] [166] .
Interesting mechanisms of resistance to agents targeting homologous recombination defect have been described. Edwards et al. [167] and Sakai et al. [168] 
